Yang Hu1, Ming Ding2, Chen Yuan3, Kana Wu2, Stephanie A Smith-Warner1, Frank B Hu4, Andrew T Chan5, Jeffrey A Meyerhardt6, Shuji Ogino7, Charles S Fuchs8, Edward L Giovannucci4, Mingyang Song9. 1. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 2. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 3. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 4. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Channing Division of Network Medicine, Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 5. Channing Division of Network Medicine, Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Clinical and Translational Epidemiology Unit and Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 6. Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. 7. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts. 8. Yale Cancer Center, New Haven, Connecticut; Department of Medicine, Yale School of Medicine, New Haven, Connecticut; Smilow Cancer Hospital, New Haven, Connecticut. 9. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Clinical and Translational Epidemiology Unit and Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: msong2@mgh.harvard.edu.
Abstract
BACKGROUND & AIMS: Few studies have examined the association between coffee intake and survival after diagnosis of colorectal cancer (CRC). We performed a prospective study to investigate the association between coffee intake after a diagnosis of CRC and mortality. METHODS: We collected data from the Nurses' Health Study (1984-2012) and Health Professionals Follow-up Study (1986-2012), following 1599 patients diagnosed with stage 1, 2, or 3 CRC. CRC was reported on questionnaires and ascertained by review of medical records and pathology reports; intake of food and beverages was determined from responses to semi-quantitative food frequency questionnaires. Participants were asked how often during the previous year that they consumed coffee, with 1 cup as the standard portion size. The first questionnaire response collected at least 6 months but not more than 4 years after diagnosis was used for assessment of post-diagnostic intake (median time from diagnosis to the dietary assessment, 2.2 years). The last semi-quantitative food frequency questionnaire prior to diagnosis was used to assess pre-diagnostic dietary intake. RESULTS: During a median of 7.8 years of follow-up, we documented 803 deaths, of which 188 were because of CRC. In the multivariable adjusted models, compared with nondrinkers, patients who consumed at least 4 cups of coffee per day had a 52% lower risk of CRC-specific death (hazard ratio [HR] 0.48; 95% CI, 0.28-0.83; P for trend=.003) and 30% reduced risk of all-cause death (HR, 0.70; 95% CI, 0.54-0.91; P for trend <.001). High intake of caffeinated and decaffeinated coffee (2 or more cups/day) was associated with lower risk of CRC-specific mortality and all-cause mortality. When coffee intake before vs after CRC diagnosis were examined, compared with patients consistently consuming low amounts (less than 2 cups/day), those who maintained a high intake (2 or more cups/day) had a significantly lower risk of CRC-specific death (multivariable HR, 0.63; 95% CI, 0.44-0.89) and death from any cause (multivariable HR, 0.71; 95% CI, 0.60-0.85). CONCLUSIONS: In an analysis data from the Nurses' Health Study and Health Professionals Follow-up Study, we associated intake of caffeinated and decaffeinated coffee after diagnosis of CRC with lower risk of CRC-specific death and overall death. Studies are needed to determine the mechanisms by which coffee might reduce CRC progression.
BACKGROUND & AIMS: Few studies have examined the association between coffee intake and survival after diagnosis of colorectal cancer (CRC). We performed a prospective study to investigate the association between coffee intake after a diagnosis of CRC and mortality. METHODS: We collected data from the Nurses' Health Study (1984-2012) and Health Professionals Follow-up Study (1986-2012), following 1599 patients diagnosed with stage 1, 2, or 3 CRC. CRC was reported on questionnaires and ascertained by review of medical records and pathology reports; intake of food and beverages was determined from responses to semi-quantitative food frequency questionnaires. Participants were asked how often during the previous year that they consumed coffee, with 1 cup as the standard portion size. The first questionnaire response collected at least 6 months but not more than 4 years after diagnosis was used for assessment of post-diagnostic intake (median time from diagnosis to the dietary assessment, 2.2 years). The last semi-quantitative food frequency questionnaire prior to diagnosis was used to assess pre-diagnostic dietary intake. RESULTS: During a median of 7.8 years of follow-up, we documented 803 deaths, of which 188 were because of CRC. In the multivariable adjusted models, compared with nondrinkers, patients who consumed at least 4 cups of coffee per day had a 52% lower risk of CRC-specific death (hazard ratio [HR] 0.48; 95% CI, 0.28-0.83; P for trend=.003) and 30% reduced risk of all-cause death (HR, 0.70; 95% CI, 0.54-0.91; P for trend <.001). High intake of caffeinated and decaffeinated coffee (2 or more cups/day) was associated with lower risk of CRC-specific mortality and all-cause mortality. When coffee intake before vs after CRC diagnosis were examined, compared with patients consistently consuming low amounts (less than 2 cups/day), those who maintained a high intake (2 or more cups/day) had a significantly lower risk of CRC-specific death (multivariable HR, 0.63; 95% CI, 0.44-0.89) and death from any cause (multivariable HR, 0.71; 95% CI, 0.60-0.85). CONCLUSIONS: In an analysis data from the Nurses' Health Study and Health Professionals Follow-up Study, we associated intake of caffeinated and decaffeinated coffee after diagnosis of CRC with lower risk of CRC-specific death and overall death. Studies are needed to determine the mechanisms by which coffee might reduce CRC progression.
Authors: W Willett; M J Stampfer; C Bain; R Lipnick; F E Speizer; B Rosner; D Cramer; C H Hennekens Journal: Am J Epidemiol Date: 1983-06 Impact factor: 4.897
Authors: Brendan J Guercio; Kaori Sato; Donna Niedzwiecki; Xing Ye; Leonard B Saltz; Robert J Mayer; Rex B Mowat; Renaud Whittom; Alexander Hantel; Al Benson; Daniel Atienza; Michael Messino; Hedy Kindler; Alan Venook; Frank B Hu; Shuji Ogino; Kana Wu; Walter C Willett; Edward L Giovannucci; Jeffrey A Meyerhardt; Charles S Fuchs Journal: J Clin Oncol Date: 2015-08-17 Impact factor: 44.544
Authors: S Salvini; D J Hunter; L Sampson; M J Stampfer; G A Colditz; B Rosner; W C Willett Journal: Int J Epidemiol Date: 1989-12 Impact factor: 7.196
Authors: Marc J Gunter; Neil Murphy; Amanda J Cross; Laure Dossus; Laureen Dartois; Guy Fagherazzi; Rudolf Kaaks; Tilman Kühn; Heiner Boeing; Krasimira Aleksandrova; Anne Tjønneland; Anja Olsen; Kim Overvad; Sofus Christian Larsen; Maria Luisa Redondo Cornejo; Antonio Agudo; María José Sánchez Pérez; Jone M Altzibar; Carmen Navarro; Eva Ardanaz; Kay-Tee Khaw; Adam Butterworth; Kathryn E Bradbury; Antonia Trichopoulou; Pagona Lagiou; Dimitrios Trichopoulos; Domenico Palli; Sara Grioni; Paolo Vineis; Salvatore Panico; Rosario Tumino; Bas Bueno-de-Mesquita; Peter Siersema; Max Leenders; Joline W J Beulens; Cuno U Uiterwaal; Peter Wallström; Lena Maria Nilsson; Rikard Landberg; Elisabete Weiderpass; Guri Skeie; Tonje Braaten; Paul Brennan; Idlir Licaj; David C Muller; Rashmi Sinha; Nick Wareham; Elio Riboli Journal: Ann Intern Med Date: 2017-07-11 Impact factor: 25.391
Authors: Wanshui Yang; Yanan Ma; Stephanie Smith-Warner; Mingyang Song; Kana Wu; Molin Wang; Andrew T Chan; Shuji Ogino; Charles S Fuchs; Vitaliy Poylin; Kimmie Ng; Jeffrey A Meyerhardt; Edward L Giovannucci; Xuehong Zhang Journal: Clin Cancer Res Date: 2018-12-13 Impact factor: 12.531
Authors: Tomotaka Ugai; Koichiro Haruki; Juha P Väyrynen; Jennifer Borowsky; Kenji Fujiyoshi; Mai Chan Lau; Naohiko Akimoto; Rong Zhong; Junko Kishikawa; Kota Arima; Shan-Shan Shi; Melissa Zhao; Charles S Fuchs; Xuehong Zhang; Marios Giannakis; Mingyang Song; Hongmei Nan; Jeffrey A Meyerhardt; Molin Wang; Jonathan A Nowak; Shuji Ogino Journal: Mayo Clin Proc Date: 2022-01 Impact factor: 11.104
Authors: Ryan H Moy; Alexander Nguyen; Jia Min Loo; Norihiro Yamaguchi; Christina M Kajba; Balaji Santhanam; Benjamin N Ostendorf; Y Gloria Wu; Saeed Tavazoie; Sohail F Tavazoie Journal: Dev Cell Date: 2022-04-28 Impact factor: 13.417
Authors: Bella Steiner; Leah M Ferrucci; Lisa Mirabello; Qing Lan; Wei Hu; Linda M Liao; Sharon A Savage; Immaculata De Vivo; Richard B Hayes; Preetha Rajaraman; Wen-Yi Huang; Neal D Freedman; Erikka Loftfield Journal: PLoS One Date: 2020-01-08 Impact factor: 3.240
Authors: Erin L Van Blarigan; Sui Zhang; Fang-Shu Ou; Alan Venlo; Kimmie Ng; Chloe Atreya; Katherine Van Loon; Donna Niedzwiecki; Edward Giovannucci; Eric G Wolfe; Heinz-Josef Lenz; Federico Innocenti; Bert H O'Neil; James E Shaw; Blase N Polite; Howard S Hochster; James N Atkins; Richard M Goldberg; Robert J Mayer; Charles D Blanke; Eileen M O'Reilly; Charles S Fuchs; Jeffrey A Meyerhardt Journal: JAMA Netw Open Date: 2020-10-01